Business Wire

The SMC Group and EMCVPA Partner to Boost Jamaica’s Creative Industries

30.6.2021 17:00:00 EEST | Business Wire | Press release

Share

Jamaica’s creative sector has received a major boost through a partnership between global entertainment marketing agency, The SMC Group, and The Edna Manley College of the Visual and Performing Arts (EMCVPA). This arrangement aims to foster the development of Jamaican talent and the island’s Creative Industries.

The venture will begin with an investment into the development of a music production studio to support local song writers, producers, and artistes. SMC also intends to recruit EMCVPA students for apprenticeships and job placements. This ground-breaking initiative will enhance the music and audio production, animation, as well as dance specialisations at the College.

The partnership is the latest positive development in the island’s creative industries which have seen considerable growth in recent years.

In the film industry, more than 4000 film-related jobs have been created in the last three years while approximately 150 foreign productions are facilitated per year​. Over 3 billion JMD in film production expenditure was contributed to GDP in the last two years,​ and approximately 65-70 percent of crews hired on most international film productions in Jamaica are local.

The country also has a growing animation industry with 15 local studios having participated in government-led programmes to increase their profitability and sustainability.

CEO of The SMC Group, Maurice Hamilton, revealed that the collaboration between the group and EMCVPA will add to the progress that has already been made in the creative industries by expanding investment into the areas of talent and content in the music and audio-visual sectors.

This is the first step of an exciting initiative to establish Jamaica and then the wider Caribbean region as a creative hub that will develop creative and business professionals as well as content,” the CEO remarked. “And for SMC, it creates a solid, efficient pipeline of creative talent to service our global clients.”

The CEO also disclosed that SMC intends to build a centre of excellence in Jamaica and will be engaging in additional investments and local partnerships.

We want to ensure that our commitment to Jamaican talent is substantive,” he insisted. “Through greater education, funding, and through our network within the global marketplace we can provide a platform from which Jamaican talent can flourish internationally.”

The island has seen several ventures over the years led by the private sector, public sector or both, which seek to advance the creative industry. Programmes such as the Business of Sustainability for Studios (BOSS) programme, JAFTA Propella film development programme, and the Film Lab initiative help entrepreneurs grow their animation and film production studios, and increase content development.

In the spirit of these collaborations between industry stakeholders, Diane Edwards, President of Jamaica’s investment and export promotions agency, JAMPRO, welcomed the cooperation between SMC and EMCVPA.

At JAMPRO, we believe that partnership is essential to building local industries and to creating valuable opportunities for Jamaica’s people, so we are pleased to see this agreement between SMC and Edna Manley College,” she said.

EMCVPA’s Vice Principal of Administration and Resource Development, Ms. Kerry Ann Henry, shared her enthusiasm for the partnership and explained that its objectives were in keeping with the college’s mission. She stated, “This is a partnership that will not just strengthen our respective organizations, it will be of enormous benefit to the country in fields related to the visual and performing arts.”

About The SMC Group

The SMC Group operates in 17 markets across the globe and has worked on campaigns for brands like The Coca-Cola Company, Net-A-Porter, Unilever, Diageo, Cartier and a host of globally recognizable names. Their projects have also involved celebrities like Jamaican Olympian Usain Bolt, Korean pop band BTS, Colombian superstar Maluma and American celebrities such as Kevin Hart, Jason Derulo and Kanye West.

ABOUT JAMPRO

The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.

For more information on JAMPRO, please visit https://dobusinessjamaica.com/.

Follow us on:
Twitter
Facebook
Instagram
LinkedIn

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Integrated Marketing Communications
Tamica Parchment
tparchment@jamprocorp.com
Tele: 876-978-7755

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye